Interference difference

Even though they are in line behind two other HIV compounds targeting chemokine receptor CCR5, Progenics Pharmaceuticals Inc. and Incyte Corp. each thinks its CCR5 inhibitor has advantages over the competition. Both companies presented data last week at the International AIDS Society meeting in Sydney.

Most HIV drugs are oral, but Progenics (PGNX, Tarrytown, N.Y.) believes PRO 140, a humanized antibody, could be developed as a first-in-class self-injectable for HIV patients.

CEO and CSO Paul Maddon, who worked on the research team that first identified CCR5's role in HIV infection in 1996, told BioCentury

Read the full 930 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE